Anika Therapeutics, Inc. (ANIK) research

Anika Therapeutics, Inc.

Sector: Biotechnology
Last price: $19.73
As of: 2026-10-05

Kresmion compiles this page from ANIK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Anika Therapeutics, Inc. (ANIK): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-29.

As of 2026-08-16, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for ANIK. Method and limitations.

COMPANY DOSSIER

See the full ANIK dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for ANIK on one page. Preview it with sample data, then open it live with a free account.

Preview the ANIK dossier

Active signals for ANIK

mediumEARNINGS_BEAT2026-07-29
Q1-2026: Beat consensus by 265.4%, EPS $0.27 vs $-0.1632 estimate
All 2026-07-29 signals →
mediumEARNINGS_BEAT2026-07-29
Q2-2026: Beat consensus by 614.7%, EPS $0.42 vs $-0.0816 estimate
All 2026-07-29 signals →

FREE, NO ACCOUNT

Every signal on ANIK, as it fires

New filings, 13F moves and cross asset signals on ANIK land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ANIK (2026Q2)

Manager / security	Market value	% portfolio	QoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 035255108 · 2026Q2	$7M	0.01%	,
TWO SIGMA INVESTMENTS, LPCUSIP 035255108 · 2026Q2	$3.7M	0.00%	,
D. E. Shaw & Co., Inc.CUSIP 035255108 · 2026Q2	$3.6M	0.00%	,
Point72 Asset Management, L.P.CUSIP 035255108 · 2026Q2	$329K	0.00%	,
MILLENNIUM MANAGEMENT LLCCUSIP 035255108 · 2026Q2	$211K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ANIK

10-Q2026-07-29
SEC EDGAR ↗
8-K2026-07-29
SEC EDGAR ↗
8-K2026-07-14
SEC EDGAR ↗
8-K2026-06-23
SEC EDGAR ↗
10-Q2026-04-30
SEC EDGAR ↗
8-K2026-04-29
SEC EDGAR ↗
10-K2026-03-03
SEC EDGAR ↗
8-K2026-02-26
SEC EDGAR ↗
8-K2026-01-08
SEC EDGAR ↗
8-K2025-11-05
SEC EDGAR ↗

ANIK against its peers

ANIK's operating margin of -9.8% ranks in the 91st percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.

Metric	ANIK	Peer median	Percentile	n
Revenue FY	113M USD	13.8M USD	97	16
Gross margin	56.6%	n/a	n/a	1
Operating margin	-9.8%	-340.4%	91	15
Net margin	-9.6%	-483.1%	91	16
Return on equity	-7.6%	-42.2%	89	21

Peers (24): NWBO, IFRX, EVMN, CAMP, PALI, STRO, IMRX, GLSI, QTTB, BCYC, ACIU, SABS, IVVD, CYDY, ZNTL, UPB, SLGL, FATE, IKT, LCTX, XFOR, EYPT, SION, PRQR. Left out: VCRE (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (ANIK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Follow ANIK on a live board

Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANIK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.